Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
तुलना करने के लिए मीट्रिक्स | 5MC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध5MCपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −1.9x | −0.8x | −0.6x | |
PEG अनुपात | −0.03 | 0.00 | 0.00 | |
क़ीमत/बुक | 2.4x | 0.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 4.6x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 75.4% | 49.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.6% | 7.8% | अनलॉक करें |